These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1298 related items for PubMed ID: 20017442

  • 1. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
    Adam Z, Krejcí M, Pour L, Stepánková S, Cermáková Z, Voska L, Teplan V, Krivanová A, Hájek R, Mayer J.
    Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
    [Abstract] [Full Text] [Related]

  • 2. [A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review].
    Adam Z, Matýková M, Krejcí M, Pour L, Kissová J, Slechtová M, Chlupová G, Stavarová Y, Simonides J, Penka M, Mayer J, Hájek R.
    Vnitr Lek; 2010 Jan; 56(1):67-78. PubMed ID: 20184115
    [Abstract] [Full Text] [Related]

  • 3. [More than 10 years of complete remission of monoclonal gammopathy of undetermined significance and cessation of light chain deposition disease-associated nephrotic syndrome following treatment with vincristine, adriamycin and high-dose dexamethasone (VAD)].
    Adam Z, Nedbálková M, Krejcí M, Pour L, Husek K, Veselý K, Cermáková Z, Krivanová A, Mayer J, Hájek R.
    Vnitr Lek; 2010 Mar; 56(3):240-6. PubMed ID: 20394211
    [Abstract] [Full Text] [Related]

  • 4. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
    Lorenz EC, Gertz MA, Fervenza FC, Dispenzieri A, Lacy MQ, Hayman SR, Gastineau DA, Leung N.
    Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
    [Abstract] [Full Text] [Related]

  • 5. Resolution of mesangial light chain deposits 3 years after high-dose melphalan with autologous peripheral blood stem cell transplantation.
    Harada K, Akai Y, Sakan H, Yamaguchi Y, Nakatani K, Iwano M, Saito Y.
    Clin Nephrol; 2010 Nov; 74(5):384-8. PubMed ID: 20979947
    [Abstract] [Full Text] [Related]

  • 6. Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support.
    Sezer O, Schmid P, Shweigert M, Heider U, Eucker J, Harder H, Sinha P, Radtke H, Possinger K.
    Bone Marrow Transplant; 1999 May; 23(9):967-9. PubMed ID: 10338056
    [Abstract] [Full Text] [Related]

  • 7. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M, Linke RP, Ho AD, Goldschmidt H.
    Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
    [Abstract] [Full Text] [Related]

  • 8. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L, Raju GM, Ganessan K, Shawgi S, Menon H, Wadhwa J, Sharma A, Singh R, Kochupillai V.
    Natl Med J India; 2003 Dec; 16(1):16-21. PubMed ID: 12715951
    [Abstract] [Full Text] [Related]

  • 9. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, Berk J, Quillen K, Skinner M.
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [Abstract] [Full Text] [Related]

  • 10. [Serum free light-chain assay for nonsecretory multiple myeloma with light chain cast nephropathy and light chain deposition disease].
    Honma R, Fukase S, Suzuki M, Omoto E.
    Rinsho Ketsueki; 2010 Apr; 51(4):270-4. PubMed ID: 20467224
    [Abstract] [Full Text] [Related]

  • 11. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
    Worel N, Schulenburg A, Mitterbauer M, Keil F, Rabitsch W, Kalhs P, Gisslinger H, Raderer M, Geissler K, Höcker P, Zielinski CC, Oberbauer R, Greinix HT.
    Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
    [Abstract] [Full Text] [Related]

  • 12. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease.
    Hassoun H, Flombaum C, D'Agati VD, Rafferty BT, Cohen A, Klimek VM, Boruchov A, Kewalramani T, Reich L, Nimer SD, Comenzo RL.
    Bone Marrow Transplant; 2008 Sep; 42(6):405-12. PubMed ID: 18574442
    [Abstract] [Full Text] [Related]

  • 13. High-dose therapy and autologous transplantation in amyloidosis-AL.
    Majolino I, Marcenò R, Pecoraro G, Scimé R, Vasta S, Liberti G, Rizzo A, Indovina A, Caronia F.
    Haematologica; 1993 Sep; 78(1):68-71. PubMed ID: 8098314
    [Abstract] [Full Text] [Related]

  • 14. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency.
    Ballester OF, Tummala R, Janssen WE, Fields KK, Hiemenz JW, Goldstein SC, Perkins JB, Sullivan DM, Rosen R, Sackstein R, Zorsky P, Saez R, Elfenbein GJ.
    Bone Marrow Transplant; 1997 Oct; 20(8):653-6. PubMed ID: 9383228
    [Abstract] [Full Text] [Related]

  • 15. Biopsy-proven resolution of renal light-chain deposition disease after autologous stem cell transplantation.
    Petrakis I, Stylianou K, Mavroeidi V, Vardaki E, Stratigis S, Stratakis S, Xylouri I, Perakis C, Petraki C, Nakopoulou L, Daphnis E.
    Nephrol Dial Transplant; 2010 Jun; 25(6):2020-3. PubMed ID: 20133281
    [Abstract] [Full Text] [Related]

  • 16. Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report.
    Kaposztas Z, Kahan BD, Katz SM, Van Buren CT, Cherem L.
    Transplant Proc; 2009 Dec; 41(10):4407-10. PubMed ID: 20005409
    [Abstract] [Full Text] [Related]

  • 17. Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation.
    Weichman K, Dember LM, Prokaeva T, Wright DG, Quillen K, Rosenzweig M, Skinner M, Seldin DC, Sanchorawala V.
    Bone Marrow Transplant; 2006 Sep; 38(5):339-43. PubMed ID: 16862166
    [Abstract] [Full Text] [Related]

  • 18. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
    Leung N, Dispenzieri A, Fervenza FC, Lacy MQ, Villicana R, Cavalcante JL, Gertz MA.
    Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
    [Abstract] [Full Text] [Related]

  • 19. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, Jo DY, Ryoo HM, Yoon SS, Lee JH, Korean Multiple Myeloma Working Party.
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [Abstract] [Full Text] [Related]

  • 20. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
    Martino M, Console G, Irrera G, Praticò G, Stelitano C, Callea V, Morabito F, Quartarone E, Musolino C, Piro E, Brugiatelli M, Iacopino P.
    Am J Hematol; 2006 Dec; 81(12):973-8. PubMed ID: 16888786
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.